pimozide has been researched along with B16 Melanoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Feng, Z; Guo, J; Jia, H; Li, J; Li, R; Liu, X; Ren, W; Sun, K; Tian, Z; Wang, M; Wang, P; Wei, T; Yang, Y; Zhao, T; Zhong, J | 1 |
| Feng, Y; Feng, Z; Guo, J; Guo, M; Jia, H; Ren, W; Song, X; Tian, Z; Wang, H; Wang, M; Wei, T; Zhao, J; Zhao, T | 1 |
| Feng, Z; Guo, J; Guo, S; Jia, H; Jia, X; Shi, X; Wang, Y; Wei, T; Zhao, T | 1 |
3 other study(ies) available for pimozide and B16 Melanoma
| Article | Year |
|---|---|
A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
Topics: Animals; Antineoplastic Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; CpG Islands; Disease Models, Animal; Drug Therapy, Combination; Humans; Immunotherapy; Killer Cells, Natural; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Oligodeoxyribonucleotides; Pimozide; Skin Neoplasms; Toll-Like Receptor 9 | 2020 |
The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Humans; Immune Tolerance; Indoleamine-Pyrrole 2,3,-Dioxygenase; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Pimozide; Skin Neoplasms; Tryptophan; Xenograft Model Antitumor Assays | 2018 |
PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide.
Topics: Animals; Antineoplastic Agents; Apoptosis; Combined Modality Therapy; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Pimozide; Programmed Cell Death 1 Receptor; RNA Interference; RNA, Small Interfering; Salmonella; Skin Neoplasms; T-Lymphocytes; Transplantation, Heterologous | 2019 |